{"disease":{"id":"pd-l1-gene-mutation","name":"pd l1 gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05819905","title":"Radiomics for prEdiction of lunG cAncer biologY","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT05110950","title":"Endobronchial Ultrasound Needle Aspiration With and Without Suction","phase":"NA","overall_status":"UNKNOWN","enrollment_count":306,"lead_sponsor_name":"Università Politecnica delle Marche","has_results":false},{"nct_id":"NCT06430502","title":"Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wuxi People's Hospital","has_results":false},{"nct_id":"NCT07279402","title":"TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Antalya Training and Research Hospital","has_results":false},{"nct_id":"NCT06634199","title":"Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT05266937","title":"Atezolizumab Plus CArboplatin Plus Nab-paclitaxel","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":49,"lead_sponsor_name":"Consorzio Oncotech","has_results":false},{"nct_id":"NCT06195683","title":"Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":23,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05330143","title":"Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Ascletis Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT04925986","title":"Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Sarah Goldberg","has_results":true},{"nct_id":"NCT05233696","title":"Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT04754815","title":"Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shirish Gadgeel","has_results":false},{"nct_id":"NCT04470674","title":"Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shirish M Gadgeel","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}